Use of Proprietary Names by Prescribers for Discontinued Brand Drug Products With Existing Generic Equivalents

被引:0
|
作者
Chi-Ming Tu
Kellie Taylor
Grace Chai
机构
[1] Food and Drug Administration,Center for Drug Evaluation and Research/Office of Surveillance and Epidemiology/Office of Medication Error Prevention and Risk Management/Division of Medication Error Prevention and Analysis
[2] Food and Drug Administration,Center for Drug Evaluation and Research/Office of Surveillance and Epidemiology/Office of Pharmacovigilance and Epidemiology/Division of Epidemiology II
关键词
prescribing practice; proprietary name; discontinued drug; drug name confusion; medication error;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:677 / 682
页数:5
相关论文
共 28 条
  • [21] Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate
    Brandis, Joel E. P.
    Kihn, Kyle C.
    Taraban, Marc B.
    Schnorr, Julia
    Confer, Alex M.
    Batelu, Sharon
    Sun, Dajun
    Rodriguez, Jason D.
    Jiang, Wenlei
    Goldberg, David P.
    Langguth, Peter
    Stemmler, Timothy L.
    Yu, Yihua Bruce
    Kane, Maureen A.
    Polli, James E.
    Michel, Sarah L. J.
    MOLECULAR PHARMACEUTICS, 2021, 18 (04) : 1544 - 1557
  • [22] VARIATION IN STATE MEDICAID USE OF BRAND-OVER-GENERIC PREFERRED DRUG LISTS
    Gabriele, S.
    Kesselheim, A. S.
    Rome, B.
    VALUE IN HEALTH, 2024, 27 (06) : S209 - S210
  • [23] Use of Identical INN "Imiglucerase" for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database
    Tsang, So-Fai
    Pandya, Shirali
    Barakov, Kristina
    Keutzer, Joan
    Lewis, Grace
    Ross, Leorah
    Freisens, Selena
    DRUG SAFETY, 2022, 45 (02) : 127 - 136
  • [24] Use of Identical INN “Imiglucerase” for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database
    So-Fai Tsang
    Shirali Pandya
    Kristina Barakov
    Joan Keutzer
    Grace Lewis
    Leorah Ross
    Selena Freisens
    Drug Safety, 2022, 45 : 127 - 136
  • [25] Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016
    Ross, Joseph S.
    Rohde, Stefanie
    Sangaralingham, Lindsey
    Brito, Juan P.
    Choi, Lauren
    Dutcher, Sarah K.
    Graham, David J.
    Jenkins, Marjorie R.
    Lipska, Kasia J.
    Mendoza, Martin
    Qiang, Yandong
    Wang, Zhong
    Wu, Yute
    Yao, Xiaoxi
    Shah, Nilay D.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (06): : 2305 - 2314
  • [26] Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers
    Ehab Rasmy Bendas
    Mamdouh R. Rezk
    Kamal A. Badr
    Clinical Drug Investigation, 2018, 38 : 439 - 448
  • [27] Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers
    Bendas, Ehab Rasmy
    Rezk, Mamdouh R.
    Badr, Kamal A.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (05) : 439 - 448
  • [28] Use of Physiologically Based Pharmacokinetic Models Coupled with Pharmacodynamic Models to Assess the Clinical Relevance of Current Bioequivalence Criteria for Generic Drug Products Containing Ibuprofen
    Cristofoletti, Rodrigo
    Dressman, Jennifer B.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (10) : 3263 - 3275